Business Wire

Research Finds Data Readiness and Infrastructure as Critical to Success in the AI Era

7.10.2025 14:00:00 CEST | Business Wire | Press Release

Share

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today unveiled a new global Enterprise AI maturity study conducted by IDC*. Thissecond annual study reveals a sharp shift in how enterprises approach artificial intelligence and confirms AI has entered a new phase where the most mature organizations prioritize data readiness, protection and security while they make impactful infrastructure decisions and investments to support current and next-gen AI.

Findings from 2024 highlighted AI’s potential to drive dramatic business outcomes, but also exposed deep gaps in infrastructure, governance, and skills. In 2025, the conversation has evolved: organizations are now confronting ROI pressures, fragmented adoption, and the need to embed data governance and security from the start.

“AI is no longer about proof of concept—it’s about proof of value,” said Syam Nair, Chief Product Officer at NetApp. “IDC’s latest research shows that the real differentiators are data preparedness and infrastructure: the companies focusing on data quality and building modern, cloud-smart, scalable, and adaptive architectures are the ones turning AI into true business impact. That’s why NetApp believes every organization needs an Intelligent Data Infrastructure to succeed in the AI era.”

Key findings from the 2025 study include:

  • Maturity pays off. AI Masters (organizations pursuing the most advanced AI infrastructure, data governance and security approaches) consistently outperform their less mature peers across every AI business outcome: Masters achieved 24.1% revenue improvement and 25.4% improvement in cost savings, far outpacing less mature peers.
  • Infrastructure remains a bottleneck. While the percentage of firms reporting that their storage required a major overhaul dropped from 63% in 2024 to 37% in 2025, 84% still say their storage is not fully optimized for AI.
  • Security is now front and center. 62% of AI Masters increased security budgets for AI initiatives in the past year, compared to just 16% of less mature organizations.
  • Agentic AI favors the Masters. With stronger data, security, and infrastructure foundations, AI Masters are already ahead. Less mature peers remain siloed in GenAI adoption, an approach that will not scale to Agentic AI’s enterprise-wide demands.

Together, these findings highlight a single point: scaling AI responsibly requires more than experimentation – it demands a trusted, modern, and intelligent data infrastructure.

“Enterprises that modernize their data pipelines, governance frameworks, security approaches, and storage architectures are the ones turning AI pilots into production-grade applications that deliver the highest measurable business outcomes,” said Dave Pearson, IDC Research Vice President, Infrastructure Solutions.

The combined 2024 and 2025 findings underscore that the difference between AI hype and AI impact lies in the data practices and architecture beneath AI initiatives. While less mature organizations may report KPI improvement, IDC finds that the greatest and most sustainable business impact comes from a focus on foundational data quality and infrastructure investments. Masters are moving beyond piecemeal upgrades toward architectures that are cloud-smart, scalable, data-aware, adaptive, and automated. In the AI era, speed, scale, security, and adaptability aren’t optional - they are key ingredients to realizing the most business value from your AI initiatives.

Methodology

In January of 2024 and June of 2025, IDC conducted a survey of +1,200 global decision makers involved in enterprise IT operations, data science, data engineering and software development related to AI initiatives. These interviews revealed in-depth information about the evolving state of AI initiatives including the array of challenges, numerous business benefits, and best practices that leading organizations have taken to achieve success.

In conducting this analysis IDC has developed an AI maturity model where organizations fall into one of four maturity levels based on their current approach to AI in terms of data and storage infrastructure, data policy and governance, resource efficiency focus, and stakeholder enablement and collaboration. These maturity levels are AI Emergents, AI Pioneers, AI Leaders, and AI Masters.

To access the full report, visit: https://www.netapp.com/media/142474-idc-2025-ai-maturity-findings.pdf

*Source: IDC InfoBrief, "Scaling Enterprise AI Responsibly: The Critical Role of Data Readiness and an Intelligent Data Infrastructure", sponsored by NetApp, doc #US53841625, October 2025

About NetApp

NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data, and workload services to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our workload services provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251007931440/en/

Contacts

Media Contact
Kenya Hayes
NetApp
kenya.hayes@netapp.com

Investor Contact
Kris Newton
NetApp
kris.newton@netapp.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye